Chia-Jen Shih1, Shuo-Ming Ou1, Pei-Wen Chao1, Shu-Chen Kuo1, Yi-Jung Lee1, Chih-Yu Yang1, Der-Cherng Tarng1, Chih-Ching Lin1, Po-Hsun Huang1, Szu-Yuan Li2, Yung-Tai Chen2. 1. From School of Medicine, National Yang-Ming University, Taipei, Taiwan (C.-J.S., S.-M.O., S.-C.K., Y.-J.L., C.-Y.Y., D.-C.T., C.-C.L., P.-H.H., S.-Y.L., Y.-T.C.); Department of Medicine, Taipei Veterans General Hospital, Yuanshan Branch, Yilan, Taiwan (C.-J.S.); Deran Clinic, Yilan, Taiwan (C.-J.S.); Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (S.-M.O., C.-Y.Y., D.-C.T., C.-C.L., S.-Y.L.); Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan (S.-M.O., Y.-T.C.); Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan (P.-W.C.); School of Medicine, Taipei Medical University, Taipei, Taiwan (P.-W.C.); National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan (S.-C.K.); Division of Infectious Diseases, Taipei Veterans General Hospital, Taipei, Taiwan (S.-C.K.); Department of Neurology, Taipei City Hospital, Ren Ai Branch, Taipei, Taiwan (Y.-J.L.); Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (P.-H.H.); and Division of Nephrology, Department of Medicine, Taipei City Hospital, Heping Fuyou Branch, Taipei, Taiwan (Y.-T.C.). 2. From School of Medicine, National Yang-Ming University, Taipei, Taiwan (C.-J.S., S.-M.O., S.-C.K., Y.-J.L., C.-Y.Y., D.-C.T., C.-C.L., P.-H.H., S.-Y.L., Y.-T.C.); Department of Medicine, Taipei Veterans General Hospital, Yuanshan Branch, Yilan, Taiwan (C.-J.S.); Deran Clinic, Yilan, Taiwan (C.-J.S.); Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (S.-M.O., C.-Y.Y., D.-C.T., C.-C.L., S.-Y.L.); Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan (S.-M.O., Y.-T.C.); Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan (P.-W.C.); School of Medicine, Taipei Medical University, Taipei, Taiwan (P.-W.C.); National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan (S.-C.K.); Division of Infectious Diseases, Taipei Veterans General Hospital, Taipei, Taiwan (S.-C.K.); Department of Neurology, Taipei City Hospital, Ren Ai Branch, Taipei, Taiwan (Y.-J.L.); Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (P.-H.H.); and Division of Nephrology, Department of Medicine, Taipei City Hospital, Heping Fuyou Branch, Taipei, Taiwan (Y.-T.C.). ytchen0117@gmail.com syli@vghtpe.gov.tw.
Abstract
BACKGROUND: Whether oral anticoagulant use should be considered in patients undergoing hemodialysis with atrial fibrillation (AF) remains controversial because of the uncertainty regarding risk-benefit assessments. The purpose of this study was to investigate the risk of ischemic stroke in patients undergoing hemodialysis with new-onset AF, in comparison with those without arrhythmia. METHODS AND RESULTS: This nationwide, population-based, propensity score-matched cohort study used data from Taiwan's National Health Insurance Research Database during 1998 to 2011 for patients on hemodialysis with new-onset nonvalvular AF and matched subjects without arrhythmia. The clinical end points were ischemic stroke (fatal or nonfatal), all-cause death, and other serious adverse cardiovascular events. In comparison with the matched cohort, patients with AF (n=6772) had higher risks of ischemic stroke (adjusted hazard ratio [aHR], 1.27; 95% confidence interval [CI], 1.13-1.43), all-cause death (aHR, 1.59; 95% CI, 1.52-1.67), in-hospital cardiovascular death (aHR, 1.83; 95% CI, 1.71-1.94), myocardial infarction (aHR, 1.33; 95% CI, 1.17-1.51), and hospitalization for heart failure (aHR, 1.90; 95% CI, 1.76-2.05). After considering in-hospital death as a competing risk, AF significantly increased the risk of heart failure (HR, 1.56; 95% CI, 1.45-1.68), but not those of ischemic stroke and myocardial infarction. Additionally, the predictive value of the CHA2DS2-VASc score for ischemic stroke was diminished in the competing-risk model. CONCLUSIONS: The risk of stroke was only modestly higher in patients undergoing hemodialysis with new-onset AF than in those without AF, and it became insignificant when accounting for the competing risk of in-hospital death.
BACKGROUND: Whether oral anticoagulant use should be considered in patients undergoing hemodialysis with atrial fibrillation (AF) remains controversial because of the uncertainty regarding risk-benefit assessments. The purpose of this study was to investigate the risk of ischemic stroke in patients undergoing hemodialysis with new-onset AF, in comparison with those without arrhythmia. METHODS AND RESULTS: This nationwide, population-based, propensity score-matched cohort study used data from Taiwan's National Health Insurance Research Database during 1998 to 2011 for patients on hemodialysis with new-onset nonvalvular AF and matched subjects without arrhythmia. The clinical end points were ischemic stroke (fatal or nonfatal), all-cause death, and other serious adverse cardiovascular events. In comparison with the matched cohort, patients with AF (n=6772) had higher risks of ischemic stroke (adjusted hazard ratio [aHR], 1.27; 95% confidence interval [CI], 1.13-1.43), all-cause death (aHR, 1.59; 95% CI, 1.52-1.67), in-hospital cardiovascular death (aHR, 1.83; 95% CI, 1.71-1.94), myocardial infarction (aHR, 1.33; 95% CI, 1.17-1.51), and hospitalization for heart failure (aHR, 1.90; 95% CI, 1.76-2.05). After considering in-hospital death as a competing risk, AF significantly increased the risk of heart failure (HR, 1.56; 95% CI, 1.45-1.68), but not those of ischemic stroke and myocardial infarction. Additionally, the predictive value of the CHA2DS2-VASc score for ischemic stroke was diminished in the competing-risk model. CONCLUSIONS: The risk of stroke was only modestly higher in patients undergoing hemodialysis with new-onset AF than in those without AF, and it became insignificant when accounting for the competing risk of in-hospital death.
Authors: Medha Airy; Tara I Chang; Victoria Y Ding; Benjamin A Goldstein; Nisha Bansal; Jingbo Niu; Sankar D Navaneethan; Mintu P Turakhia; Wolfgang C Winkelmayer Journal: Nephrol Dial Transplant Date: 2018-09-01 Impact factor: 5.992
Authors: Jeffrey M Ashburner; Alan S Go; Yuchiao Chang; Margaret C Fang; Lisa Fredman; Katie M Applebaum; Daniel E Singer Journal: J Am Geriatr Soc Date: 2016-11-12 Impact factor: 5.562
Authors: Juan Jesus Carrero; Marco Trevisan; Manish M Sood; Peter Bárány; Hong Xu; Marie Evans; Leif Friberg; Karolina Szummer Journal: Clin J Am Soc Nephrol Date: 2018-07-20 Impact factor: 8.237
Authors: Jingbo Niu; Maulin K Shah; Jose J Perez; Medha Airy; Sankar D Navaneethan; Mintu P Turakhia; Tara I Chang; Wolfgang C Winkelmayer Journal: Am J Kidney Dis Date: 2018-11-16 Impact factor: 8.860